Effect of cannabis on glutamate signalling in the brain

A systematic review of human and animal evidence

Marco Colizzi, Philip McGuire, Roger G. Pertwee, Sagnik Bhattacharyya*

*Corresponding author for this work

Research output: Contribution to journalLiterature review

45 Citations (Scopus)

Abstract

Use of cannabis or delta-9-tetrahydrocannabinol (Delta 9-THC), its main psychoactive ingredient, is associated with psychotic symptoms or disorder. However, the neurochemical mechanism that may underlie this psychotomimetic effect is poorly understood. Although dopaminergic dysfunction is generally recognized as the final common pathway in psychosis, evidence of the effects of Delta 9-THC or cannabis use on dopaminergic measures in the brain is equivocal. In fact, it is thought that cannabis or Delta 9-THC may not act on dopamine firing directly but indirectly by altering glutamate neurotransmission. Here we systematically review all studies examining acute and chronic effects of cannabis or Delta 9-THC on glutamate signalling in both animals and man. Limited research carried out in humans tends to support the evidence that chronic cannabis use reduces levels of glutamate-derived metabolites in both cortical and subcortical brain areas. Research in animals tends to consistently suggest that Delta 9-THC depresses glutamate synaptic transmission via CB1 receptor activation, affecting glutamate release, inhibiting receptors and transporters function, reducing enzyme activity, and disrupting glutamate synaptic plasticity after prolonged exposure. (C) 2016 Elsevier Ltd. All rights reserved.

Original languageEnglish
Pages (from-to)359-381
Number of pages23
JournalNeuroscience & Biobehavioral Reviews
Volume64
DOIs
Publication statusPublished - May 2016

Keywords

  • Cannabis
  • Delta-9-tetrahydrocannabinol
  • Glutamate signalling
  • Glutamatergic synaptic transmission
  • Cannabinoid receptor type 1
  • Functional genetic-variation
  • Long-term depression
  • Rat cerebellum
  • Delta-9-tetrahydrocannabinol exposure
  • Synaptic plasticity
  • Prefrontal Cortex
  • Delta(9)-tetrahydrocannabinol exposure
  • Extracellular glutamate
  • Attentional salience
  • Hippocampal-neurons

Cite this

Effect of cannabis on glutamate signalling in the brain : A systematic review of human and animal evidence. / Colizzi, Marco; McGuire, Philip; Pertwee, Roger G.; Bhattacharyya, Sagnik.

In: Neuroscience & Biobehavioral Reviews, Vol. 64, 05.2016, p. 359-381.

Research output: Contribution to journalLiterature review

@article{b279e855eb1f4b348908521fb38ee0b9,
title = "Effect of cannabis on glutamate signalling in the brain: A systematic review of human and animal evidence",
abstract = "Use of cannabis or delta-9-tetrahydrocannabinol (Delta 9-THC), its main psychoactive ingredient, is associated with psychotic symptoms or disorder. However, the neurochemical mechanism that may underlie this psychotomimetic effect is poorly understood. Although dopaminergic dysfunction is generally recognized as the final common pathway in psychosis, evidence of the effects of Delta 9-THC or cannabis use on dopaminergic measures in the brain is equivocal. In fact, it is thought that cannabis or Delta 9-THC may not act on dopamine firing directly but indirectly by altering glutamate neurotransmission. Here we systematically review all studies examining acute and chronic effects of cannabis or Delta 9-THC on glutamate signalling in both animals and man. Limited research carried out in humans tends to support the evidence that chronic cannabis use reduces levels of glutamate-derived metabolites in both cortical and subcortical brain areas. Research in animals tends to consistently suggest that Delta 9-THC depresses glutamate synaptic transmission via CB1 receptor activation, affecting glutamate release, inhibiting receptors and transporters function, reducing enzyme activity, and disrupting glutamate synaptic plasticity after prolonged exposure. (C) 2016 Elsevier Ltd. All rights reserved.",
keywords = "Cannabis, Delta-9-tetrahydrocannabinol, Glutamate signalling, Glutamatergic synaptic transmission, Cannabinoid receptor type 1, Functional genetic-variation, Long-term depression, Rat cerebellum, Delta-9-tetrahydrocannabinol exposure, Synaptic plasticity, Prefrontal Cortex, Delta(9)-tetrahydrocannabinol exposure, Extracellular glutamate, Attentional salience, Hippocampal-neurons",
author = "Marco Colizzi and Philip McGuire and Pertwee, {Roger G.} and Sagnik Bhattacharyya",
year = "2016",
month = "5",
doi = "10.1016/j.neubiorev.2016.03.010",
language = "English",
volume = "64",
pages = "359--381",
journal = "Neuroscience & Biobehavioral Reviews",
issn = "0149-7634",
publisher = "PERGAMON-ELSEVIER SCIENCE LTD",

}

TY - JOUR

T1 - Effect of cannabis on glutamate signalling in the brain

T2 - A systematic review of human and animal evidence

AU - Colizzi, Marco

AU - McGuire, Philip

AU - Pertwee, Roger G.

AU - Bhattacharyya, Sagnik

PY - 2016/5

Y1 - 2016/5

N2 - Use of cannabis or delta-9-tetrahydrocannabinol (Delta 9-THC), its main psychoactive ingredient, is associated with psychotic symptoms or disorder. However, the neurochemical mechanism that may underlie this psychotomimetic effect is poorly understood. Although dopaminergic dysfunction is generally recognized as the final common pathway in psychosis, evidence of the effects of Delta 9-THC or cannabis use on dopaminergic measures in the brain is equivocal. In fact, it is thought that cannabis or Delta 9-THC may not act on dopamine firing directly but indirectly by altering glutamate neurotransmission. Here we systematically review all studies examining acute and chronic effects of cannabis or Delta 9-THC on glutamate signalling in both animals and man. Limited research carried out in humans tends to support the evidence that chronic cannabis use reduces levels of glutamate-derived metabolites in both cortical and subcortical brain areas. Research in animals tends to consistently suggest that Delta 9-THC depresses glutamate synaptic transmission via CB1 receptor activation, affecting glutamate release, inhibiting receptors and transporters function, reducing enzyme activity, and disrupting glutamate synaptic plasticity after prolonged exposure. (C) 2016 Elsevier Ltd. All rights reserved.

AB - Use of cannabis or delta-9-tetrahydrocannabinol (Delta 9-THC), its main psychoactive ingredient, is associated with psychotic symptoms or disorder. However, the neurochemical mechanism that may underlie this psychotomimetic effect is poorly understood. Although dopaminergic dysfunction is generally recognized as the final common pathway in psychosis, evidence of the effects of Delta 9-THC or cannabis use on dopaminergic measures in the brain is equivocal. In fact, it is thought that cannabis or Delta 9-THC may not act on dopamine firing directly but indirectly by altering glutamate neurotransmission. Here we systematically review all studies examining acute and chronic effects of cannabis or Delta 9-THC on glutamate signalling in both animals and man. Limited research carried out in humans tends to support the evidence that chronic cannabis use reduces levels of glutamate-derived metabolites in both cortical and subcortical brain areas. Research in animals tends to consistently suggest that Delta 9-THC depresses glutamate synaptic transmission via CB1 receptor activation, affecting glutamate release, inhibiting receptors and transporters function, reducing enzyme activity, and disrupting glutamate synaptic plasticity after prolonged exposure. (C) 2016 Elsevier Ltd. All rights reserved.

KW - Cannabis

KW - Delta-9-tetrahydrocannabinol

KW - Glutamate signalling

KW - Glutamatergic synaptic transmission

KW - Cannabinoid receptor type 1

KW - Functional genetic-variation

KW - Long-term depression

KW - Rat cerebellum

KW - Delta-9-tetrahydrocannabinol exposure

KW - Synaptic plasticity

KW - Prefrontal Cortex

KW - Delta(9)-tetrahydrocannabinol exposure

KW - Extracellular glutamate

KW - Attentional salience

KW - Hippocampal-neurons

U2 - 10.1016/j.neubiorev.2016.03.010

DO - 10.1016/j.neubiorev.2016.03.010

M3 - Literature review

VL - 64

SP - 359

EP - 381

JO - Neuroscience & Biobehavioral Reviews

JF - Neuroscience & Biobehavioral Reviews

SN - 0149-7634

ER -